Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Foghorn Therapeutics Inc
(NQ:
FHTX
)
5.630
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Foghorn Therapeutics Inc
< Previous
1
2
Next >
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
April 06, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
March 09, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
March 01, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
January 09, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
December 05, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
November 22, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
November 14, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
November 09, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
November 08, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
October 27, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
October 26, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
October 20, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.